A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study
AuthorChajès, Véronique; Assi, Nada; Biessy, Carine; Ferrari, P.; Rinaldi, Sabina; Slimani, Nadia; Lenoir, GM; Baglietto, L; His, Mathilde; Boutron-Ruault, M.C.; Trichopoulou, A; Lagiou, P.; Katsoulis, M; Kaaks, R.; Kuhn, T.; Panico, S.; Pala, V; Masala, G; Bueno-De-Mesquita, Hendrik Bastiaan; Peeters, P.H.; van Gils, Carla; Hjartåker, Anette; Olsen, Karina Standahl; Borgund Barnung, Runa; Barricarte, A; Redondo-Sánchez, Daniel; Menéndez, V; Amiano, P.; Wennberg, Maria; Key, T.; Khaw, K.T.; Merritt, M.A.; Riboli, E.; Gunter, M.J.; Romieu, I.
Background: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting.
Materials and methods: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours.
Results: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4–Q1) 1.37; 95% confidence interval (CI), 1.14–1.64; P for trend = 0.0001, q value = 0.004] as well as a high desaturation index (DI16) (16:1n–7/16:0) [OR (Q4–Q1), 1.28; 95% C, 1.07–1.54; P for trend = 0.002, q value = 0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3–T1)=2.01; 95% CI, 1.03–3.90; P for trend = 0.047], whereas no association was found for ER-positive tumours (P-heterogeneity =0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor.
Conclusion: These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.
PublisherOxford University Press (OUP)
CitationChajès, V., Assi, N., Biessy, C., Ferrari, P., Rinaldi, S., Slimani, N., ... Romieu, I. (2017). A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. Annals of Oncology, 28(11), 2836-2842. https://doi.org/10.1093/annonc/mdx482
Showing items related by title, author, creator and subject.
A comprehensive analysis of the androgen receptor gene and risk of breast cancer. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) Lund, Eiliv; Cox, David G.; Blanché, Hélène; Pearce, Celeste L.; Calle, Eugenia E.; Colditz, Graham A.; Pike, Malcolm C.; Albanes, Demetrius; Allen, Naomi E.; Amiano, Pilar; Berglund, Göran; Boeing, Heiner; Buring, Julie; Burtt, Noel; Canzian, Federico; Chanock, Stephen; Flavel-Chapelon, Françoise; Feigelson, Heather Spencer; Freedman, Matthew; Haiman, Christopher A.; Hankinson, Susan E.; Henderson, Brian E.; Hoover, Robert; Hunter, David J.; Kaaks, Rudolf; Kolonel, Laurence; Kraft, Peter; LeMarchand, Loic; Palli, Domenico; Peeters, Petra H.M.; Riboli, Elio; Stram, Daniel O.; Thun, Michael; Tjönneland, Anne; Trichopoulos, Dimitrios; Yeager, Meredith (Journal article; Tidsskriftartikkel; Peer reviewed, 2006-09-20)Introduction Androgens have been hypothesised to influence risk of breast cancer through several possible mechanisms, including their conversion to estradiol or their binding to the oestrogen receptor and/or androgen receptor (AR) in the breast. Here, we report on the results of a large and comprehensive study of the association between genetic variation in the AR gene and risk of breast cancer ...
What are the molecular consequences of germline mutations in breast and ovarian cancer susceptibility genes in a Norwegian breast and ovarian cancer population? Jarhelle, Elisabeth (Doctoral thesis; Doktorgradsavhandling, 2018-06-01)It is estimated that 5-10% of breast cancers (BC) and 25% of ovarian cancers (OC) are caused by inherited sequence variants in genes. In the mid 90’s, the two genes BRCA1 and BRCA2 were discovered to be directly associated with increased risk of BC and OC. Molecular screening of these two genes has revealed several disease causing variants as well as variants of unknown clinical significance (VUS). ...
Hereditary breast and ovarian cancer. Diversity of genetic causes of HBOC in a Norwegian breast and ovarian cancer patient cohort, BRCA2 c.8331+2C>T - a Norwegian founder mutation Skarsfjord, Siri Hermansen (Master thesis; Mastergradsoppgave, 2017-05-14)Hereditary breast and ovarian cancer (HBOC) causes 5-10 % of breast cancer cases and 25 % of ovarian cancer cases. About 24 % of HBOC are caused by deleterious variants in BRCA1 and BRCA2. Currently, more than 25 different genes have been associated with HBOC, including BRCA1 and BRCA2, many of which encode proteins participating in homologous recombination repair (HRR) and mismatch repair (MMR). ...